In an era when big price tag hikes for prescription medicine are pretty much assured to draw criticism, is there any circumstance when a 486% enhance for a medicine may possibly appear to be justified?
A smaller enterprise known as Harrow argues that it can make the circumstance for an injectable eye remedy that has been used to overcome various serious situations. Firm executives retain the medication, which has been mostly out of inventory for the previous few decades, involves considerable financial commitment in order to restore a steady offer and, additionally, was considerably underpriced.
But some market professionals say a profitable relaunch will largely rely on reactions amongst eye specialists. In addition, the notable cost hike also highlights a question about the extent to which penalties that are assessed by Medicaid and Medicare — which are levied for increasing drug price ranges previously mentioned inflation — are from time to time deemed to be a cost of accomplishing business.
Continue to STAT+ to browse the complete story…